logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Full-Life Technologies To Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

Nov 29, 2022•about 3 years ago

Acquiring Company

Full-Life Technologies

Acquired Company

Focus-X Therapeutics

ShanghaiBiotechnology

Description

Full-Life Technologies, a fully integrated global radiotherapeutics company, today announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology. The acquisition expands Full-Life's pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.

Company Information

Company

Full-Life Technologies

Location

Shanghai, Shanghai, China

About

Full-Life Technologies ("Full-Life") is a fully-integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed